Summary Deregulated expression of c-MYC occurs in a broad range of human cancers and is often associated with poor prognosis, indicating a key role for this oncogene in tumour progression. However ...

Acute myeloid leukemia (AML) is an aggressive cancer affecting the blood and bone marrow that progresses rapidly, making ...

MYC belongs to a family of proteins containing the basic helix-loop-helix and leucine zipper (bHLH-LZ) domains. 1 Structurally, these two functional domains are located adjacent to each other toward ...

Thirty-one sailors participated in the Menantic Yacht Club’s (MYC) first series of Sunfish races this past Sunday in West ...

A heartbroken mom lost a second son to gun violence when her 17-year-old boy was shot and killed during a chaotic water gun ...

UCLA scientists have uncovered a surprising survival strategy in cells, especially cancer cells, that may help explain how ...

Kevin Murach, an assistant professor at the University of Arkansas, Fayetteville who previously received a multimillion-dollar National Institutes of Health grant to study the impact of exercise on ...

Aggressive forms of acute myeloid leukemia (AML) remain challenging to treat, especially in patients with FLT3-ITD mutations.

Breast cancer is the most frequent malignancy among women worldwide, and all subtypes of breast cancer involve upregulation of the c-Myc gene, making it a compelling therapeutic target. G-rich regions ...

Preliminary results from a phase I clinical trial show that the first in class MYC inhibitor Omomyc (OMO-103) has few side effects, is tolerable, and stabilizes disease in some patients.

Oncoprotein Myc is known to be dysregulated in about 70% of cancers, and it is highly expressed in leukemias and lymphomas. Targeting Myc has not been successful and is still an unmet clinical need ...